Latest news
Probe Scientific’s MicroEye® gains EU approval
30 May 2007
Single-use blood sampling device eliminates needle puncture in blood sampling.
Probe Scientific Ltd, announces that it been awarded regulatory approval to market its device MicroEye® in Europe. MicroEye® is a sterile single-use, minimally invasive blood sampling device which allows continuous blood sampling in collaboration with pre-existing access devices, thereby avoiding repeated needle puncture for the patient.
CE marking, an important milestone for Probe, allows the device to begin clinical evaluations with selected customers in the UK and Europe. Leading clinical researchers are keen to evaluate the MicroEye® and to demonstrate its value in solving blood collection problems associated with cutting edge medical research and clinical trials. MicroEye® is the first product of the series; future products will employ Probe’s proprietary platform tool to focus on automated sampling and sensing technologies for immediate analysis at a patient’s bedside in a wide range of clinical markets.
Neil Smith, CEO of Probe Scientific, said: “The regulatory process is a key step in the development of new medical devices. Our European approval means we can start to market, evaluate, and further develop, our product in Europe. We will also use the approval of MicroEye® to initiate the regulatory work for the USA.”
The awarding of the CE Mark is a promising development in Probe’s progress towards producing a device that can be sold into the high potential global market for automated blood sampling and analysis.